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The mechanisms for controlling food intake involve mainly an interplay between gut, brain,
and adipose tissue (AT), among the major organs. Parasympathetic, sympathetic, and other
systems are required for communication between the brain satiety center, gut, and AT.
These neuronal circuits include a variety of peptides and hormones, being ghrelin the
only orexigenic molecule known, whereas the plethora of other factors are inhibitors of
appetite, suggesting its physiological relevance in the regulation of food intake and energy
homeostasis. Nutrients generated by food digestion have been proposed to activate G-
protein-coupled receptors on the luminal side of enteroendocrine cells, e.g., the L-cells.
This stimulates the release of gut hormones into the circulation such as glucagon-like
peptide-1 (GLP-1), oxyntomodulin, pancreatic polypeptides, peptide tyrosine tyrosine, and
cholecystokinin, which inhibit appetite. Ghrelin is a peptide secreted from the stomach
and, in contrast to other gut hormones, plasma levels decrease after a meal and potently
stimulate food intake. Other circulating factors such as insulin and leptin relay information
regarding long-term energy stores. Both hormones circulate at proportional levels to body
fat content, enter the CNS proportionally to their plasma levels, and reduce food intake.
Circulating hormones can influence the activity of the arcuate nucleus (ARC) neurons of
the hypothalamus, after passing across the median eminence. Circulating factors such as
gut hormones may also influence the nucleus of the tractus solitarius (NTS) through the
adjacent circumventricular organ. On the other hand, gastrointestinal vagal afferents con-
verge in the NTS of the brainstem. Neural projections from the NTS, in turn, carry signals
to the hypothalamus. The ARC acts as an integrative center, with two major subpopu-
lations of neurons influencing appetite, one of them coexpressing neuropeptide Y and
agouti-related protein (AgRP) that increases food intake, whereas the other subpopula-
tion coexpresses pro-opiomelanocortin (POMC) and cocaine and amphetamine-regulated
transcript that inhibits food intake. AgRP antagonizes the effects of the POMC product,
α-melanocyte-stimulating hormone (α-MSH). Both populations project to areas important
in the regulation of food intake, including the hypothalamic paraventricular nucleus, which
also receives important inputs from other hypothalamic nuclei.
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INTRODUCTION
Nutrients created by the digestion of food are proposed to activate
G-protein-coupled receptors on the luminal side of enteroen-
docrine cells, e.g., the L-cells. This stimulates the release of gut
hormones. The hormones released from the gut and the adipose
tissue (AT) play an important role in the regulation of food intake
and energy expenditure (1).
Many circulating signals, including gut hormones, can influ-
ence the activity of the arcuate nucleus (ARC) neurons directly,
after passing across the median eminence. The ARC is adja-
cent to the median eminence, a circumventricular organ with
fenestrated capillaries and hence an incomplete blood–brain bar-
rier (BBB) (2). The ARC plays a crucial role in the regulation
of food intake and energy homeostasis. The ARC contains two
populations of neurons with opposing effects on food intake
(3). Medially located orexigenic neurons express neuropeptide
Y (NPY) and agouti-related protein (AgRP) (4, 5). Anorexigenic
neurons (i.e., those inhibiting appetite) in the lateral ARC express
alpha-melanocyte-stimulating hormone (α-MSH) derived from
pro-opiomelanocortin (POMC) and cocaine and amphetamine-
regulated transcript (CART) (6). The balance between the activi-
ties of these neuronal circuits is critical to body weight regulation.
In contrast, other peripheral signals influence the hypothal-
amus indirectly via afferent neuronal pathways and brainstem
circuits. In this context, the gastrointestinal vagal afferents are
activated by mechanoreceptors and chemoreceptors, and converge
in the nucleus of the tractus solitaries (NTS) of the brainstem.
Neuronal projections from the NTS, in turn, carry signals to the
hypothalamus (1, 7). Gut hormones also alter the activity of the
ascending vagal pathway from the gut to the brainstem. In the case
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of ghrelin and peptide tyrosine tyrosine (PYY), there is some evi-
dence for a direct action of both on the ARC and an action via the
vagus nerve and brainstem.
The axons of these neurons project to “second-order” neu-
rons, located in part in the paraventricular nucleus (PVN),
where the anorexigenic substances thyrotropin-releasing hormone
(TRH), corticotropin-releasing hormone (CRH), and oxytocin
are secreted, and in part, in the lateral hypothalamic (LH) and
perifornical area (PFA), where the orexant molecules melanin-
concentrating hormone (MCH) and orexins are produced. When
adipose signals reach the ARC, anorexigenic peptides are released
which activate a catabolic circuit. In contrast, the activation of the
anabolic pathway leads to the release of orexigenic peptides and
occurs when adiposity signal concentrations in the brain are low,
thus indicating the urgency to replenish fuel stores (8).
PERIPHERAL GUT HORMONES
OREXIGENIC PEPTIDES
Ghrelin
Ghrelin is a peptide consisting of 28 amino acids and is unusual
among peptide hormones in that Ser3 is n-octanoylated.
Ghrelin is present in X/A-like cells, which account for approx-
imately 20% of the endocrine cell population in adult oxyntic
glands (9). Ghrelin-immunoreactive cells are also found in the
duodenum, jejunum, ileum, and colon. In the intestine, the ghre-
lin concentration gradually decreases from the duodenum to the
colon. This peptide is also secreted from other organs such as
the hypothalamus and pancreas of rats and, in addition, ghrelin
mRNA is expressed in various organs (10, 11). The best known fac-
tor for the regulation of ghrelin secretion is feeding. The plasma
ghrelin concentration increases when fasting, and decreases after
food intake. The factors involved in the regulation of ghrelin secre-
tion have not yet been identified. Blood glucose levels may be a
most probable candidate; thus, oral or intravenous administration
of glucose decreasing plasma ghrelin concentrations exhibits a
nocturnal increase and are low in obese people and high in
lean people (12–18). Exogenous growth hormone (GH) decreases
stomach ghrelin mRNA expression and plasma ghrelin concentra-
tion, but does not affect stomach ghrelin stores (19).
The localization of ghrelin receptors on vagal afferent neurons
in the rat nodose ganglion suggests that ghrelin signals from the
stomach are transmitted to the brain via the vagus nerve (20, 21).
In summary, ghrelin is secreted primarily from the stomach in
response to hunger and starvation, circulates in the blood and
serves as a peripheral signal, informing the central nervous system
(via vagus nerve) to stimulate feeding. Ghrelin-containing neu-
rons are also found in the ARC of the hypothalamus, a region
involved in appetite regulation (1). In fact, intracerebroventricu-
lar (ICV) injection of ghrelin increases cumulative food intake and
decreases energy expenditure, resulting in body weight gain (21–
24). To stimulate the release of the orexigenic peptides, ghrelin-
containing neurons send efferent fibers onto NPY and AgRP-
expressing neurons. On the other hand, to suppress the release of
the anorexigenic peptide, ghrelin-containing neurons send effer-
ent fibers onto POMC neurons. The ARC is also a target of leptin,
an appetite-suppressing hormone produced in AT (25). Leptin
directly inhibits the appetite-stimulating effects of NPY and AgRP,
whereas hypothalamic ghrelin blocks leptin-induced reduction of
feeding. Thus, ghrelin and leptin have a competitive interaction in
the regulation of feeding.
Ghrelin is only a hunger signal from peripheral tissues. Intra-
venous and sub-cutaneous injections of ghrelin increase food
intake; likewise, peripherally injected ghrelin stimulates hypo-
thalamic neurons and food intake (22, 23, 26–28). Because the
rate at which peripheral ghrelin passes the BBB has been shown
to be very low, peripheral ghrelin must activate the appropriate
hypothalamic regions via an indirect pathway (29).
In addition, it has been reported that the enzyme ghrelin O-
acyl transferase, essential for ghrelin acylation, is modulated by
nutrient availability, depends on specific dietary lipids as acy-
lation substrates. Thus, this mechanism may act as a nutrient
sensor by using absorbable fatty acids to signal to the brain that
high caloric food is available, leading to optimization of nutrient
partitioning (30).
ANOREXIGENIC AGENTS
Peptide tyrosine tyrosine
Peptide tyrosine tyrosine has 36 amino acids, contains several
tyrosine residues, and requires C-terminal amidation for biologic
activity.
Low levels of PYY are detected in enteroendocrine cells in the
stomach, and levels increase distally along the small and large intes-
tine, reaching their highest levels in cells in the colon and rectum
(31). PYY is released from enteroendocrine L-cells lining the distal
gastrointestinal tract in proportion to caloric intake. Plasma levels
of PYY rise within 30 min of a meal and, in humans, circulating
levels plateau at 1–2 h post-prandially, remaining elevated for up
to 6 h (32). Protein-rich meals cause the greatest increase in PYY
levels compared to other macronutrients (33, 34). The anorectic
effects of PYY3–36 appear to be mediated centrally via the ARC.
PYY1–36 and PYY3–36 exert their effects through the NPY family
(35). PYY1–36 binds with similar affinity to NPY receptors. How-
ever, PYY3–36 is a selective high affinity at the Y2 receptor subtype
(Y2R) (36) thought to be the receptor responsible for reduction of
food intake by PYY. A vagal brainstem-mediated pathway may also
be involved in the actions of circulating PYY3–36. PYY is present
in enteric nervous plexus neurons innervating the gastrointesti-
nal tract and the Y2R receptor has been identified on the vagus
nerve (37), the effects of PYY3–36 on satiety and central control
of appetite are clear. Most are mediated via anorectic neuronal
populations in the ARC, but vagal/brainstem-mediated pathways
and peripheral effects of PYY on gastric emptying and intestinal
motility may also play a part.
Pancreatic polypeptide
Pancreatic polypeptide (PP) is an amidated 36-amino acid peptide
that belongs to the “PP-fold” family of peptides. It is released post-
prandially under vagal control by pancreatic islet PP cells (38). PP
is comparable to other anorectic intestinal peptides such as PYY,
being secreted in proportion to caloric intake.
Pancreatic polypeptides bind to all the members of the Y recep-
tor family, but have the highest affinity for the Y4 receptor subtype
(39). The effects of PP are likely to be mediated by the ventromedial
hypothalamus (VMH) and paraventricular hypothalamus (PVN)
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and brainstem [area postrema (AP) and ARC] (40), in areas central
to the control of appetite. The anorectic effects of PP in humans
appear to be independent of changes in gastric motility (41).
Cholecystokinin
Cholecystokinin (CCK) is released post-prandially from the small
intestine (42), and has also been shown to co-localize with PYY in
L-cells (43). It is released in response to saturated fat, long chain
fatty acids, amino acids, and small peptides that would normally
result from protein digestion (44, 45). CCK1 receptors are present
in peripheral tissues such as the pancreas, gallbladder, and on vagal
afferent nerve fibers innervating the gut (46). Furthermore, CCK1
receptors have been identified in areas within the CNS involved in
the regulation of food intake such as the NTS, AP, and dorsomedial
hypothalamus (47). The CCK2 receptor has a different distribu-
tion. It is found in the cortex, hypothalamus, vagal afferents, and
gastric mucosa, once again encompassing several areas known to
be involved in appetite regulation. In humans, intravenous admin-
istration of physiological doses of CCK reduces food intake and
increases the perception of fullness (48).
Leptin
Leptin is a 167-amino acid protein known to suppress appetite
and regulate energy expenditure. Leptin is secreted mainly by
adipocytes (49), but has also been found in the stomach (50) and
the pituitary gland (51). Nevertheless, AT remains its main source
responsible for 95% of leptin production (51). Circulating leptin
levels are positively correlated with body mass index (BMI) and AT
mass. Adipocytes possess large numbers of GH receptors (GHR)
and it is known that GH directly regulates leptin gene expression
(52). Furthermore, the production of leptin is influenced by sev-
eral regulators, being stimulated by insulin and blood glucose but
inhibited by sympathetic activity, lipolytic catecholamines, and
free fatty acids (FFA). Leptin production correlates positively with
AT mass (53) and is independent of the adiposity. In these reason,
leptin levels are higher in women than in men (54). In humans,
there is a highly organized pattern of leptin secretion over a 24-h
period. In general, the circadian pattern is characterized by basal
levels between 08:00 and 12:00 hours, rising progressively to peak
between 24:00 and 04:00 hours, and receding steadily to a nadir by
12:00 hours (55). The nocturnal rise in leptin secretion is entrained
to mealtime probably due to cumulative hyperinsulinemia of the
entire day (54). Leptin is secreted in a regular pulsatile fashion with
an interpeak interval of about 44 min, and the circadian rhythm
is attributable solely to increased pulse height. Circulating leptin
is transported across the BBB via a saturable process. Starvation
reduces transport, whereas refeeding increases the transport of
leptin across the BBB (56, 57).
Leptin is transported across the BBB by a saturable trans-
porter system (58) and exerts its anorectic effect via the ARC,
where both NPY/AgRP and POMC/CART neurons express leptin
receptors (59). Leptin inhibits NPY/AgRP neurons and activates
POMC/CART neurons (60, 61), resulting in reduced food intake.
It also influences in the secretion of neuropeptides engaged in
energy homeostasis such as CRH, TRH, and BDNF (62–65). Addi-
tionally, leptin stimulates the adrenergic system, thus increasing
energy expenditure (66). In addition to its interaction with central
neural processes, there is evidence of a synergy between leptin and
the episodic satiety factor CCK discussed previously (67). Lep-
tin has been shown to enhance the satiating effect of CCK (68).
In addition, leptin-induced down-regulation of the hippocam-
pal somatostatinergic system may potentiate its anorexigenic
effect (69).
Amylin
Amylin is a 37-amino acid peptide, also known as islet amyloid
polypeptide. In mammals, amylin is co-released with insulin from
pancreatic β-cells in response to food intake and has an anorec-
tic effect (70). Amylin seems to decrease food intake through both
central and peripheral mechanisms and, indirectly, by slowing gas-
tric emptying. The AP plays a predominant role in peripheral
amylin’s satiating effect, involving a direct activation of AP neu-
rons by blood-borne amylin. Its anorectic effect may, in part, be
due to reduced expression of orexigenic neuropeptides in the LH
area (71). There is evidence that amylin may also exert its effects
through serotonergic, histaminergic, and dopaminergic systems.
Insulin
Insulin is produced in β-cells of the pancreatic islets of Langerhans
and enters the brain from the circulation acting on hypothala-
mic neuron located mainly in the ARC, to reduce energy intake.
There is also a specific insulin transport across the BBB regu-
lated by a saturable mechanism that involves insulin receptors in
brain microvessels. ICV infusion or systemic injection of insulin
results in a dose-dependent suppression of food intake. Central
action of insulin promotes anorexia because it decreases NPY
and stimulates POMC expression (72). Insulin binds to its recep-
tors highly expressed in POMC/CART and NPY/AgRP neurons.
Insulin and leptin both activate POMC neurons, but they seem
to differentially regulate AgRP, with leptin inhibiting and insulin
stimulating its synthesis (73). Insulin deficiency is associated with
increased NPY,while insulin administration inhibits hypothalamic
NPY expression.
Glucagon-like peptides
Pre-proglucagon gene expression is limited to α-cells in the pan-
creas, L-cells in the gut, and neurons in the brain stem nucleus
of the NTS. Whereas post-translational processing of proglucagon
in the pancreas leads to the formation of glucagon and the major
proglucagon fragment, proteolytic cleavage in the L-cells of the
gut and in the NTS yields the peptides glicentin, oxyntomodulin
(OXM), glucagon-like peptides 1 and 2 (GLP-1 and -2) (74). After
a meal, GLP-1 and GLP-2 are secreted in parallel in the circu-
lation. GLP-1, is perhaps best known as a gut-derived incretin
hormone. GLP-1 is a 30-amino acid peptide and one of several
cleavage products of the pre-proglucagon gene. It is secreted by
the enteroendocrine L-cells of the distal intestine in response to
incoming nutrients (75). GLP-1 is also a neurotransmitter synthe-
sized by a small population of neurons in the NTS in the caudal
brainstem (76). Food ingestion promotes the release of GLP-1
from L-cells in the intestine, which activates vagal afferents. (77).
GLP-2 is a peptide highly conserved across different mammalian
species. Its main biological effects are related to the regulation of
energy absorption and maintenance of mucosal morphology, and
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function and integrity of the intestine. In the gastrointestinal tract,
GLP-2 increases the uptake of luminal nutrients, including sugars
and lipids, by augmenting the activity and expression of nutri-
ents transporter. Its influence on appetite regulation is unclear but
recent studies have shown that intraperitoneal injection of GLP-2
reduces food intake in mice (78).
Oxyntomodulin
Oxyntomodulin is a 37-amino acid peptide released post-
prandially from L-cells in proportion to caloric intake. OXM (79)
causes a reduction of neuronal activity in the ARC, PVN, and
supraoptic nucleus. This pattern of activation is distinct from that
of GLP-1 under the same conditions (80), implying that these two
hormones act via different hypothalamic pathways. OXM reduces
food intake in normal weight human volunteers when adminis-
tered intravenously or subcutaneously (81). There is evidence that
OXM may increase energy expenditure in humans (82).
Bombesin
Bombesin is a tetradecapeptide that was isolated from amphibian
skin and is similar in structure to mammalian gastrin-releasing
peptide (GRP) and neuromedin B (83, 84). Bombesin (85, 86) and
GRP administration (87) decrease food intake in lean human sub-
jects but not in obese women (88). Peripheral or central injection
of bombesin reduces food intake that is not blocked by vago-
tomy (89, 90). Bombesin also activates the sympathetic nervous
system (91). In animals that have been starved or have ventrome-
dial hypothalamic lesions, bombesin produces a profound drop in
temperature because the sympathetic nervous system cannot be
activated (91, 92).
Obestatin
Recently, it has been demonstrated that preproghrelin under-
goes additional proteolytic cleavage, generating a 23-amino acid
peptide, which has been named obestatin. In contrast to ghre-
lin, obestatin has anorexigenic effects, reduces gastric emptying,
inhibits jejunal contractions, and suppresses body weight gain
(93). However, several recent studies performed in rats and mice
under various experimental conditions did not reproduce these
results (94, 95). Pan et al. (96) reported that obestatin is unable to
cross the BBB and is rapidly degraded in the circulation; this was
confirmed by Vergote et al. (97). An alternative hypothesis is that
obestatin exerts its effects on eating and drinking through direct
interactions with the gastrointestinal system. Indeed, Zhang et al.
(98) observed decreased contractile activity of jejunum muscle
strips in vitro and suppression of gastric emptying in vivo after
obestatin treatment. Thus, the inhibition of jejunal contraction
could generate an afferent vagal signal to induce satiety in the
brain. Recently, Fujimiya et al. (99) supposed that obestatin may
act on the obestatin receptor on vagal afferent nerve terminals,
and corticotropin-releasing factor (CRF) and urocortin-2 neu-
rons in the hypothalamus may mediate the action of obestatin to
inhibit the gastroduodenal motility via CRF1-R and CRF2-R in
the brain (100).
CENTRAL HYPOTHALAMIC PEPTIDES
The hypothalamus contains several important nuclei that are asso-
ciated with energy homeostasis and feeding regulation. The LH is
a feeding center, the VMH is the satiety center, and the ARC is an
integrated center for feeding regulation.
HYPOTHALAMIC OREXIGENIC PEPTIDES
Neuropeptide Y
The ARC is the major site of expression for NPY within neurons
in the hypothalamus that project to PVN, dorsomedial hypo-
thalamus (DMH), LH, and other hypothalamic sites. Although
NPY can produce diverse effects on behavior and other func-
tions, its most noticeable effect is the stimulation of feeding after
central administration (101). NPY synthesis in the ARC and its
release into the PVN, the most abundant projection, is regu-
lated by inhibitory afferent signals such as leptin and insulin
and stimulatory signal as glucocorticoids. The NPY neurons are
potential hypothalamic targets for leptin and inhibition of the
synthesis, and probably release of NPY seems to partly explain
the ability of leptin to induce hypophagia and weight loss. Insulin
has been shown to inhibit NPY synthesis and secretion in the
PVN. Five G-protein-coupled NPY receptors have been identi-
fied – Y1, Y2, Y4, Y5, and Y6. Y5 receptors have been implicated as
important receptors that mediate the feeding effects of NPY (102,
103). The Y5 receptor is expressed at relatively high levels in the
LHA, close to the site where NPY acts most potently to stimulate
feeding (104).
Agouti-gene related protein
Agouti-gene related protein is a 132-amino acid peptide. Within
the CNS, AgRP is expressed exclusively in the ARC and AgRP
mRNA co-localizes with NPY mRNA in 95% of NPY positive cells
in this nucleus (105). Rossi et al. have shown that like NPY, AgRP
is an orexigenic peptide when injected ICV (106) or directly into
the PVN or DMH (107). Uniquely, AgRP acts as an endogenous
antagonist of the melacortin-3 (MC3R) and melacortin-4 receptor
(MC4R) (108). It is likely AgRP plays a modulatory role in feed-
ing. It may be that AgRP is more important during conditions of
high energy requirements, such as pregnancy and lactation, under
which it has been shown to be more highly expressed (109).
Melanin-concentrating hormone
Melanin-concentrating hormone is an orexygenic cyclic 19-amino
acid neuropeptide. Within the hypothalamus (MCH), it is highly
expressed in the LH and zona incerta (110) and has orexigenic
effects after ICV infusion (111). Interest regarding the effector
mechanisms by which MCH is orexigenic has largely focused on
the MCHR1 receptors in the nucleus accumbens shell (AcbSh)
where MCH injection decreases neuronal firing in medium spiny
neurons (112). The nucleus accumbens is thought to be involved
in motivational aspects of eating.
Hypocretins/orexins
The hypocretins (1 and 2; also known as orexins A and B) are exci-
tatory neuropeptides that are produced in cell bodies of the LH
area, but have extensive projections to many regions. The hypocre-
tin/orexins bind to orexin receptor 1 and 2 (OXR1 and OXR2),
which arise from two separate genes. The distribution of the two
receptors is different. Within the hypothalamus, OX1R is the most
highly expressed in the PVN (113).
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Orexins are appetite-stimulating neuropeptides. Orexin neu-
ronal cell bodies are present in the LH and DMH, and orexin-
containing neuronal fibers are distributed in several nuclei, with
abundant projections to the ARC. Orexin-containing neurons
project to NPY-containing neurons in the ARC, and NPY neu-
rons express the OX1R (114). Furthermore, orexins increase the
cytosolic Ca2+ concentration in NPY neurons isolated from the
ARC (115). These results indicate that NPY neurons receive exci-
tatory signals from orexin-containing neurons in the LH. The
distribution of the two receptors is also different; within the hypo-
thalamus, OX1R is most highly expressed in the VMH and OX2R
is most highly expressed in the PVN (113).
Galanin
Galanin is a 29-amino acid C-terminally amidated (30 amino
acid, non-amidated in humans), found in the brain and the gut.
Galanin coexists with GABA, noradrenaline, 5-hydroxytryptamine
(5-HT), and NPY in several regions of the brain. Hypothalamic
galanin neurology is found largely in the PVN, supraoptic nucleus
of hypothalamus (SON), and ARC. Many galanin-positive fibers
as well as galanin-positive neurons have been demonstrated in
the dorsal vagal complex, suggesting that galanin produces its
effects by involving vagal neurons. The nucleus of the solitary
tract is the major source of the galanin terminals in the dorsal
vagal complex. There are two cloned galanin subtype receptors:
GalR1 and GalR2 are majorly distributed in the hypothalamus,
PVN, amygdale, hippocampus, brainstem, spinal cord, peripheral
nervous system, and other tissues (116). This peptide partici-
pates in modulating learning, memory, feeding, inflammation,
pain threshold control, sexual behavior, insulin, and pituitary hor-
mone release (117–119). Acute central administration of galanin
has been reported to increase fat consumption.
Galanin-like peptide
Galanin-like peptide (GALP) is a novel 60-amino acid peptide,
with residues 9–21 being identical to the biologically active N-
terminal (1–13) portion of galanin (120). In situ hybridization
studies have shown that GALP mRNA is distributed within the
periventricular regions of the ARC (121, 122) in the median
eminence, and in the pituitary gland of the rat (123). NPY-
containing axon terminals are closely apposed (opposed) to GALP-
containing neurons in the ARC (124). Moreover, Cunningham
et al. (125) demonstrated, using double-label in situ hybridiza-
tion, that GALP-containing neurons in the macaque expressed the
NPY Y1 receptor, suggesting that NPY regulates GALP neurons
in the ARC. However, whether NPY activates GALP is yet to be
determined.
Cerebellin1
Cerebellin1 (Cbln1) is highly expressed in the hypothalamus. ICV
administration of Cbln1 increases food intake and the release of
NPY from hypothalamic explants and reduces plasma thyroid-
stimulating hormone (TSH) levels after postinjection in rats with-
out adverse behavioral effects. Cbln1 mRNA expression levels
were increased in the ventromedial nucleus of the hypothalamus
in fasted rats. These data suggest that Cbln1 is a novel orex-
igenic peptide, which may mediate its effects via hypothalamic
NPY (126).
HYPOTHALAMIC ANOREXIGENIC PEPTIDES
Cocaine and amphetamine-regulated transcript
Cocaine and amphetamine-regulated transcript is a neuropeptide
which appears to be a powerful physiological anorexic signal.
CART mRNA was identified on the basis of its increase fol-
lowing cocaine or amphetamine treatment in rats (127). CART
peptide is localized in specific areas of the hypothalamus includ-
ing the periventricular nucleus, dorsomedial nucleus, perifornical
regions, lateral nucleus, and the ARC. In the PVN, CART mRNA is
co-localized with vasopressin and CRF-containing neurons (128).
Melanocortins
The melanocortins are bioactive peptides derived from the precur-
sor molecule POMC via tissue-specific post-translational cleavage
(56). The POMC gene is expressed at physiologically significant
levels in a number of mammalian tissues including anterior and
intermediate pituitary, skin, the immune system, and hypothal-
amic neurons. The repertoire of products derived from POMC
by any tissue is determined by the specificities of the convertases
expressed in the tissue (129, 130). The intermediate lobe of the
pituitary yields α-melanocytes-stimulating hormone (α-MSH),
a peptide which activates melanocortin (MC) 3 and MC4 MC
receptors and inhibits food intake. The MC3R and MC4R recep-
tors are found in areas known to be involved in regulation of
energy balance, but also in other regions such as cerebral cortex
and hippocampus. Bioactive peptides generated in hypothalamic
neurons act as endogenous ligands for the MC4R, a key molecule
underlying appetite control and energy homeostasis (131).
Glucagon-like peptides
In the brain, release of GLP-1 within the nucleus of the solitary
tract NTS and from projections of GLP-1 neurons to the PVN
leads to GLP-1 receptor activation, which promotes satiety and
anorexia. Activated GLP-1 neurons of the NTS also project to the
ARC to modulate vagal motor outflow to the pancreas and other
tissues not depicted, increasing insulin secretion from the β-cells in
states of hyperglycemia and suppresses glucagon from the α-cells,
leading to lowering of blood glucose. Systemic GLP-1 may also
access the brain via leaks in the BBB such as the subfornical organ
and the AP, as demonstrated to occur in rats. The intravenous
administration of GLP-1 to normal and obese humans decreases
food intake in a dose-dependent manner (132) as well as reduc-
ing gastric emptying (133, 134). These effects are thought to be
mediated through vagal and brainstem pathways since peripheral
administration of GLP-1 activates neurons within the brainstem
in rats (1, 135).
The distribution of the co-localized peptide GLP-2 displays a
perfect overlap with GLP-1 in the CNS, with the highest concen-
tration in the diffuse ventral part of the dorsomedial nucleus (76,
136). When injected into the lateral ventricle, GLP-2 has a marked
inhibitory effect on feeding. The effect of GLP-2 on feeding is
both behaviorally and pharmacologically specific (76). The CNS
GLP-2R is essential for the control of feed behavior. Glp-2r dele-
tion in POMC neurons increases food intake with amplified meal
frequency and accelerates gastric emptying, suggesting that CNS
GLP-2 is a key satiety signal for the physiological short-term con-
trol of feeding behavior and gastric motility and contributes to the
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long-term homeostatic control of energy balance (or body weight).
Moreover, activation of GLP-2R signaling suppresses food intake
and gastric emptying through the MC4R signaling pathway. Guan
et al. (137) findings suggest that gastric emptying is a key process
for the short-term control of feeding behavior and POMC neuron-
mediated suppression of food intake may be executed through
decelerating gastric emptying (137).
Corticotropin-releasing factor
Corticotropin-releasing factor or CRH is a 41-amino acid
mammalian neurohormone that is best known as the major
physiological regulator of pituitary ACTH secretion. CRH is highly
expressed in PVN neurons and, when centrally injected, inhibits
food intake and reduces body weight in rats. Peripheral admin-
istration of human CRH increases energy expenditure and fat
oxidation in humans. Leptin infusion stimulates CRH expres-
sion, while pretreatment with a CRH antagonist attenuates the
leptin-induced reduction of food intake and body weight.
Neurotensin
Neurotensin (NT) is a 13-amino acid peptide. NT is produced in
the ARC, PVN, and DMH of the hypothalamus and its microin-
jection into the PVN decreases food intake. NT neurons appear to
play an anorectic role downstream of leptin as ICV leptin infusion
into the PVN stimulates NT synthesis in association with reduced
food intake (138, 139). These results suggest that leptin action may
be mediated, at least in part, by NT.
Nesfatin-1
In the early 1990s, a protein was identified in mouse (140)
and human cell lines (141) and termed nucleobindin or NEFA
(DNA binding/EF-hand/acidic amino acid-rich region). Until
now, two nucleobindins have been identified, namely nucle-
obindin1 (NUCB1) and nucleobindin2 (NUCB2 or NEFA).
NUCB2 contains a 24-amino acid N-terminal signal peptide and
a 396-amino acid sequence that is highly conserved in rodents
and humans (142), pointing toward its physiological relevance.
NUCB2 was localized on the plasma membrane and in the
cytoplasm.
In 2006, Oh and colleagues (143) were the first to describe that
putative post transcriptional processing of NUCB2 by the enzyme
pro-hormone convertase (PC)-1/3 results in nesfatin-1 (amino
acid 1–82), nesfatin-2 (amino acid 85–163), and nesfatin-3 (amino
acid 166–396) (143). So far, the biological activity has only been
demonstrated in nesfatin-1 and the fragment nesfatin-124–53.
The initial report described the expression of NUCB2 mRNA
substantiated by nesfatin-1 inmmunohistochemistry in rat hypo-
thalamic and brainstem nuclei involved in the regulation of inges-
tive behavior, such as the PVN, supraoptic nucleus, ARC, LH, zona
incerta, and NTS (143). Nesfatin-1 inmmunopositive neurons
co-localize with a number of brain transmitters (8, 12–17).
Nesfatin-1 directly inhibits ARC neurons containing NPY. A
recent study provided compelling evidence for the involvement of
an oxytocin pathway in the inhibitory effect of nesfatin-1 on food
intake (144). Nefastatin-1 is also likely to act in series through
the recruitment of the central MC and corticotrophin-releasing
factor 2 (CRF2) signaling systems to reduce food intake. The
anorexic action of peripheral nesfatin-1/NUCB2 may be medi-
ated by vagal afferents projecting to the nucleus of the solitary
tract in addition to a potential hormonal action via crossing of the
BBB (145).
Central nesfatin-1/NUCB2 mediates its anorexigenic effect via
activation of melanocortin3/4 and CRF2 signaling and also by
hyperpolarizing neurons containing the orexigenic peptide, NPY.
Nesfatin-1 also activates the hypothalamic magnocellular oxy-
tocinergic system, which could reduce food intake and delay
gastric emptying. Peripheral nesfatin-1 can reach the brain via
the circulation and crossing of the BBB and/or a direct action on
circumventricular organs as well as on the modulation of vagal
afferent activity.
Immunostaining in the peripheral tissues confirmed the
expression of nesfatin-1/NUCB2 protein in the rat stomach and,
additionally, in pancreatic endocrine islets of Langerhans, testis,
and pituitary gland. Similarly, nesfatin-1-immunopositive cells
of the endocrine pancreas exclusively co-localize with insulin in
β-cells (146, 147). These findings suggest a differential release
of nesfatin-1 and ghrelin from the stomach and nesfatin-1 and
insulin from the pancreas, which warrants further investigation.
The prominent and exclusive endocrine distribution of nesfatine-
1/NUCB2 in cells of the stomach and pancreas support the fact
that nesfatin-1 may act as a gut–brain peptide to influence food
intake and glucose homeostasis. The anorexic action of peripheral
nesfatin-1/NUCB2 may be mediated by vagal afferents project-
ing to the nucleus of the solitary tract, in addition to a potential
hormonal action through crossing of the BBB (145).
PITUITARY HORMONES
VASOPRESSIN
Vasopressin significantly reduces food intake over a 4 h period
in experimental animals. The reduction in food intake, particu-
larly in the first 30 min of feeding, is not significantly impaired by
vagotomy, suggesting that its peripheral mechanism of action is
different from that of CCK or enterostatin (148).
MELANOCYTE-STIMULATING HORMONE
In yellow mice, that overexpress AgRP, treated with melanocyte-
stimulating hormone (MSH) there is a substantial increase in food
intake and weight gain which is 30–100 times greater than that of
the acylated form (α) of MSH. In contrast, injection of αMSH
produces a much more potent darkening of the melanocyte than
does dMSH.
GROWTH HORMONE
Following treatment with GH, hypophysectomized animals
increase their food intake and growth. This finding could be a
direct effect of GH on feeding centers or a may be due to a second
stimulation by an enhanced flux of amino acids into new proteins
that leads to an increase in feeding.
Growth hormone stimulates lipolysis in the AT and, par-
ticularly, in the visceral and sub-cutaneous depots (149–152).
Hormone-sensitive lipase (HSL or LIPE) is a crucial enzyme impli-
cated in this process. GH may also modulate the expression of
the lipid droplet associating protein, CIDE-A (cell-death-inducing
DFF45-like effector). CIDE proteins have been associated with
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lipid droplets, where they facilitate lipid accumulation and inhibit
lipolysis. Unlike the AT, GH induces FFA uptake into skeletal
muscle by up-regulation of LPL expression (153, 154). The re-
sterification of triacylglycerides (TAG) from FFAs results in gen-
eration of intermediates such as diacylglycerol and ceramides that
activate PKC isoforms. PKC can down-regulate insulin signaling
by several mechanisms (155, 156). GH secretion is diminished
in obesity, where increased FFA levels may have a suppressive
effect on GH secretion. The hyperinsulinemia associated with this
pathological situation may also contribute to decreased GH secre-
tion (156). Thus, in this manner, the GH-induced increase in FFA
uptake and TAG synthesis could result in insulin resistance. These
data also suggest that GH induces a shift in substrate utilization
from glucose to lipids in the skeletal muscle.
IMPLICATIONS FOR OBESITY AND METABOLIC SYNDROME
OBESITY
The etiology of obesity is believed to be extremely complex and
includes a combination of excess dietary calories and decreased
physical activity, coupled with either some predisposing genetic
factors or metabolic disorders (157–159).
Ghrelin
Although the role of ghrelin in the etiology of obesity is not under-
stood, it is considered a vital target because of its capacity to induce
a positive energy balance state (160, 161). Supporting the relevance
of the ghrelin pathway regarding obesity, recent studies by Wort-
ley et al. and Zigman et al. (162, 163) show that the absence of
both ghrelin or its receptor GHS-1a protects mice against diet-
induced obesity. In addition, ghrelin immunization in rats has
been reported to reduce body weight gain (164) and catalytic anti-
ghrelin antibodies in C57BL/6 mice reduce refeeding for 6 h after
a 24-h starvation and maintain high levels of energy expenditure
(165). Nevertheless, the immunization against ghrelin failed to
cause long-term body weight reduction (166) and some studies
with mice from a pure C57BL/6 background knockout for ghre-
lin or ghrelin receptor suggest only negligibly small differences in
food intake and body weight under caloric restriction or a high-
fat diet compared with wild-type mice (167). Finally, the absence
of ghrelin in ob/ob mice does not seem to decrease food intake
or body weight in this mouse model, although lowering blood
glucose substantially (168, 169).
Leptin
Obese patients with three risk factors for metabolic syndrome
have lower leptin levels (170). Mutations in the leptin receptor
(Ob-R) gene are responsible for monozygotic obesity in rodents
and humans. In obesity, there is also a defective transport of lep-
tin across the BBB, which suggests the existence of central leptin
resistance (171). This resistance could be inherited or secondary
to obesity, associated with a less efficient transport of leptin via the
BBB or abnormalities in leptin signaling (171).
Insulin
Insulin is a signal of satiety and obesity (172). Reduced expression
or deletion of insulin receptors in the brain leads to hyperfagia
and obesity (173).
Hypothalamic–pituitary–adrenal axis
There is a neuroendocrine integration of the stress centers in the
CNS with centers that control appetite (174). Acute stress exerts
an anorexigenic effect though stimulation of POMC/CART neu-
rons by increased CRH levels and an additional decrease of NPY
secretion (174, 175). CRH activates the hypothalamic–pituitary–
adrenal axis with an increase in cortisol secretion which, in turn,
inhibits the activation of the HPA axis. This is responsible for the
anorexigenic effect of glucocorticoids in the case of acute stress.
Chronic stress is associated with chronic activation of the HPA axis
and prolonged glucocorticoid secretion. Chronically elevated lev-
els of glucocorticoids exert orexigenic effects caused by inhibition
of CRH and stimulation of NPY expression (174, 175). Several
studies have also shown increased responsiveness of the HPA axis
in obese patients to different stimuli and in a dynamic test with
neuropeptides and small doses of dexamethasone (176). Abdomi-
nal obesity is also associated with attenuated negative feedback in
the HPA axis (173).
Growth hormone
Growth hormone secretion is consistently reduced in obesity (177,
178). Consequently, low GH secretion could further contribute to
accumulation of abdominal fat (156). Obesity-induced hyperin-
sulinemia, hypoadiponectinemia, leptin resistance, and increased
bioactive insulin-like growth factor-1 (IGF-1) and FFA levels could
suppress GH secretion from the pituitary by various mechanisms
mentioned above. Reduced GH secretion further increases fat
accumulation and, thus, exacerbates the obesity condition. More-
over, reduced GHR expression and increased expression of trun-
cated GHR (∆GHR) in the AT results in a GH-resistant state that
also contributes to the complications associated with obesity (156).
Thyroid hormones
The hypothalamic–pituitary–thyroid (HPT) axis may play a direct
role in appetite regulation. Hypothyroidism reduces energy expen-
diture and causes weight gain, while hyperthyroidism exerts the
opposite effect (179). TRH, after peripheral or central adminis-
tration, exerts a direct anorexigenic effect (180). Similarly, central
administration of TSH causes inhibition of food intake in rats.
Triiodothyronine (T3) which directly stimulates food intake at the
hypothalamic level, can also cross the BBB and reach the CNS
directly and then be transported to the ARC (181). Peripheral
administration of T3 increases NPY and reduces POMC expres-
sion (179). Direct injection of T3 into the VMN also exerts an
orexigenic effect in rats (179).
METABOLIC SYNDROME
Metabolic syndrome is due to cluster of cardiovascular risk fac-
tors that includes obesity, hypertension, insulin resistance, and
glucose and lipid metabolic abnormalities (182, 183). Metabolic
syndrome is associated with an increased risk of cardiovascu-
lar disease (CVD) and type 2 diabetes mellitus, even before the
development of glucose intolerance (169, 183, 184).
Galanin
The effect of the galanin peptide family on the metabolic syndrome
includes increased food consumption and the preference for a
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high-fat diet, which elevates the probability of obesity and dys-
lipidemia, and decreased insulin resistance and blood pressure to
relieve the risk for type 2 diabetes mellitus and hypertension (185).
Adiponectin and leptin
Adiponectin, an anti-atherogenic and anti-inflammatory adipocy-
tokine involved in glucose and lipid metabolism, improves insulin
sensitivity (186). Lower levels of adiponectin were observed in
patients with high blood pressure, hyperglycemia, low HDL-C,
and hypertriglyceridemia, and in obese patients with MS (187).
Brooks et al. showed that a low level of circulating adiponectin
may be used as a possible biomarker for MS (188). Leptin, an
anti-obesity adipocytokine, regulates body weight by modifying
energy levels and increasing the metabolic rate while decreasing
food intake. Most overweight and obese patients show resistance
to leptin at the receptor level, and therefore, have higher leptin
levels than non-overweight individuals (189). Serum leptin lev-
els in patients with MS are higher than those in healthy controls
(190). Adiponectin and leptin levels show an inverse correlation
with each other (191).
García-Cardona et al. studied the correlation between obesity
and insulin resistance and methylation frequency of the leptin and
adiponectin promoters in obese adolescents, with the aim of iden-
tifying epigenetic markers that might be used as tools to predict
and follow-up the physiological alterations associated with the
development of the metabolic syndrome. Obese adolescents with-
out insulin resistance showed higher and lower circulating levels
of leptin and adiponectin, respectively, along with increased plas-
matic concentrations of insulin and triglycerides. The methylation
frequency of CpG sites located at −51 and −31 nt relative to the
transcription start site of the leptin gene dropped dramatically in
obese adolescents with insulin resistance (192).
Neuropeptide Y
Bray et al. studied positive association of an NPY gene variant
(880I/D) with obesity in Mexican-American families (193). Addi-
tionally, there have been many studies examining the functional
Leu7Pro polymorphism (rs16139). This single nucleotide poly-
morphism (SNP) has been associated with a large number of con-
ditions related to obesity and metabolic syndrome traits, including
increased BMI in adults (194), development of obesity in young
adults (195), risk of hypertension (196), high plasma low-density
lipoprotein-cholesterol (LDL-c) in children and adults (196, 197),
and elevated plasma TAG (198). This variant has been associated
with metabolic syndrome in patients with coronary artery disease
(199). This SNP has also been shown to correlate with high birth
body weight in preschoolers, the risk of an accelerated atheroscle-
rotic process or carotid atherosclerosis in adults (196, 200), and
the risk of type 2 diabetes mellitus in adults (201). Additionally,
Josune-Olza et al. validated the association between the SNPs NPY
rs16147 genotype and BMI in Spanish children, observing higher
BMI values in TT homozygotes as compared with heterozygous C
allele carriers (202).
Pro-opiomelanocortin
Yoo et al. (203) demonstrated that high POMC methylation in
cord blood was associated with lower birth weight and children
with high POMC methylation in cord blood showed higher TAG
and higher insulin concentrations in blood. Thus, POMC methy-
lation status in cord blood may be an early predictive marker of
future metabolic syndrome.
CONCLUSION
The control of energy balance depends critically on the CNS. The
various CNS regions that control energy homeostasis are accessi-
ble to numerous circulating factors discussed above. Within these
central locations are specific neuronal populations that recognize
these signals and act in the network to integrate the multiple
inputs, and help to regulate appetite (68). In particular, the hypo-
thalamus is a center of integration of several nutrient signals. It
can sense and integrate variations in adiposity and gastric hor-
mones, as well as nutrients, and also receives neuroanatomical
projections from other nutrient sensors, mainly within the brain-
stem. In addition, it also integrates these signals with cognitive
forebrain-descending information to coordinate neuroendocrine,
behavioral, and metabolic effectors of energy balance.
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